Review top news and interview highlights from the week ending November 25, 2022.
Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
Omidubicel’s BLA was originally accepted for priority review in August of this year.
The director of the CCU/ICU at Saint John’s Health Center discussed unmet respiratory treatment needs in the beginning of the COVID-19 pandemic.
Sarnaik discussed several potential areas of innovation on the horizon.
Statistically significant improvements in cognitive development were only seen in the cohort of patients younger than 30 months.
A marketing authorization application for etranacogenedezaparvovec is currently under review by the EMA.